Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure

被引：40

作者：

Askevold E.T. ^{[1
,2
,4
]}

Gullestad L. ^{[1
,2
,4
,6
]}

Dahl C.P. ^{[1
,2
,4
]}

Yndestad A. ^{[1
,4
,5
,6
]}

Ueland T. ^{[1
,6
]}

Aukrust P. ^{[1
,3
,5
,6
]}

机构：

[1] Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, 0424 Oslo

[2] Department of Cardiology, Oslo University Hospital, Rikshospitalet, 0424 Oslo

[3] Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Rikshospitalet, 0424 Oslo

[4] K.G. Jebsen Cardiac Research Centre, Oslo University Hospital, Rikshospitalet, 0424 Oslo

[5] K.G. Jebsen Inflammation Research Centre, Oslo University Hospital, Rikshospitalet, 0424 Oslo

[6] Aukrust Faculty of Medicine, Oslo University Hospital, Rikshospitalet, 0424 Oslo

来源：

Current Heart Failure Reports | 2014年 / 11卷 / 2期

关键词：

Cytokine; Heart failure; Inflammation; Interleukin-6; Risk prediction; Sgp130; Therapy;

D O I：

10.1007/s11897-014-0185-9

中图分类号：

学科分类号：

摘要：

Both experimental and clinical evidence accumulated over the last couple of decades has linked inflammatory activation to the initiation and progression of chronic heart failure (HF). Circulating levels of inflammatory mediators are associated with cardiac function and inform risk prediction in patients, but the effect of anti-inflammatory therapy in HF remains uncertain. Interleukin (IL)-6 type cytokines are central to the inflammatory response, and convey their signals through the ubiquitously expressed glycoprotein (gp) 130 receptor subunit. IL-6-type/gp130 signaling therefore represents an inflammatory nexus, with inherent potential for disease modification. This review focuses on the current knowledge of IL-6/gp130 signaling in relation to HF, with a particular emphasis on the role of soluble gp130 (sgp130), a signaling pathway modulator. Biological aspects of sgp130 and IL-6 signaling are discussed, as are potential novel therapeutic approaches to modulate this central inflammatory signaling pathway. © Springer Science+Business Media 2014.

引用

页码：146 / 155

页数：9

共 108 条

[51] Villegas S., Villarreal F.J., Dillmann W.H., Leukemia Inhibitory Factor and Interleukin-6 downregulate sarcoplasmic reticulum Ca<sup>2+</sup> ATPase (SERCA2) in cardiac myocytes, Basic Research in Cardiology, 95, 1, pp. 47-54, (2000)
[52] Patten M., Kramer E., Bunemann J., Wenck C., Thoenes M., Wieland T., Long C., Endotoxin and cytokines alter contractile protein expression in cardiac myocytes in vivo, Pflugers Archiv European Journal of Physiology, 442, 6, pp. 920-927, (2001)
[53] Hirota H., Izumi M., Hamaguchi T., Sugiyama S., Murakami E., Kunisada K., Fujio Y., Oshima Y., Nakaoka Y., Yamauchi-Takihara K., Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure, Heart and Vessels, 19, 5, pp. 237-241, (2004)
[54] Tsutamoto T., Wada A., Maeda K., Mabuchi N., Hayashi M., Tsutsui T., Ohnishi M., Fujii M., Matsumoto T., Yamamoto T., Wang X., Asai S., Tsuji T., Tanaka H., Saito Y., Kuwahara K., Nakao K., Kinoshita M., Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy, Journal of the American College of Cardiology, 38, 5, pp. 1485-1490, (2001)
[55] Gwechenberger M., Pacher R., Berger R., Zorn G., Moser P., Stanek B., Huelsmann M., Comparison of soluble glycoprotein 130 and cardiac natriuretic peptides as long-term predictors of heart failure progression, Journal of Heart and Lung Transplantation, 24, 12, pp. 2190-2195, (2005)
[56] Eiken H.G., Oie E., Damas J.K., Yndestad A., Bjerkeli V., Aass H., Simonsen S., Geiran O.R., Tonnessen T., Christensen G., Froland S.S., Gullestad L., Attramadal H., Aukrust P., Myocardial gene expression of leukaemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failure, European Journal of Clinical Investigation, 31, 5, pp. 389-397, (2001)
[57] Zolk O., Ng L.L., O'Brien R.J., Weyand M., Eschenhagen T., Augmented expression of cardiotrophin-1 in failing human hearts is accompanied by diminished glycoprotein 130 receptor protein abundance, Circulation, 106, 12, pp. 1442-1446, (2002)
[58] Plenz G., Song Z.F., Tjan T.D.T., Koenig C., Baba H.A., Erren M., Flesch M., Wichter T., Scheld H.H., Deng M.C., Activation of the cardiac interleukin-6 system in advanced heart failure, European Journal of Heart Failure, 3, 4, pp. 415-421, (2001)
[59] Yan A.T., Yan R.T., Cushman M., Redheuil A., Tracy R.P., Arnett D.K., Et al., Relationship of interleukin-6 with regional and global left-ventricular function in asymptomatic individuals without clinical cardiovascular disease: Insights from the Multi-Ethnic Study of Atherosclerosis, Eur Heart J, 31, 7, pp. 875-882, (2010)
[60] Harhay M.O., Tracy R.P., Bagiella E., Barr R.G., Pinder D., Hundley W.G., Et al., Relationship of CRP, IL-6, and fibrinogen with right ventricular structure and function: The MESA-Right Ventricle Study, Int J Cardiol, 168, 4, pp. 3818-3824, (2013)

← 1 2 3 4 5 6 7 8 9 10 →